Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc.

The latest announcement is out from Baxter International ( ($BAX) ). On November 19, 2025, Baxter International announced an increase in the maximu...

Baxter International Ups Tender Offer to $600 Million

Baxter International ( ($BAX) ) has shared an update. On November 19, 2025, Baxter International Inc. announced the commencement of cash tender off...

Baxter International Launches $300M Cash Tender Offers

A&nbsp;class action&nbsp;lawsuit was filed against&nbsp;Baxter International ($BAX) on October 16, 2025. The plaintiffs (shareholders) alleged that...

Baxter (BAX) Hit with Class Action Lawsuit over Defective Novum LVP Infusion Pumps

In a report released on October 30, Robbie Marcus from J.P. Morgan maintained a Hold rating on Baxter International, with a price target of $19.00....

Baxter International (BAX) Gets a Hold from J.P. Morgan

In a report released today, Patrick Wood from Morgan Stanley maintained a Sell rating on Baxter International, with a price target of $19.00. The c...

Baxter International (BAX) Gets a Sell from Morgan Stanley

Barclays analyst Matt Miksic maintained a Buy rating on Baxter International today and set a price target of $36.00. The company’s shares closed ye...

Barclays Keeps Their Buy Rating on Baxter International (BAX)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Baxter International, with a price target of $36.00. The company’s...

Market Cap	$9.25B	P/E Ratio	7.76
52W High	$37.74	52W Low	$17.40
Div Yield	4.0%	Payout Ratio	98.9%
EPS Growth 3Y	-35.6%	52W Position	4.5%
Overall Score	52	Value Score	80
Quality Score	--	Technical Score	25

EPS Current Est	$2.36	EPS Next Est	$2.38
EPS Growth Est	+0.8%	DPS Growth 3Y	-1.6%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BAX	$18.31	+5.11%	8.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BAX	$18.31	+5.1%	8.28M
3
4
5
6

BAX

BAX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Baxter International Inc. Data in Excel

Get Baxter International Inc. Data in Excel